Hope Rugo, Md, Offers Key Takeaways For Physicians Regarding Keynote-355

Hope Rugo, MD, offers key takeaways for physicians regarding KEYNOTE-355

Hope Rugo, MD, considers chemotherapy recommendations based on findings from KEYNOTE-355

Hope Rugo, MD, shares the design and outcomes of KEYNOTE-355 presented at SABCS 2020

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...

KEYNOTE-355: pembrolizumab in triple-negative breast cancer

Immunotherapy for TNBC: IMpassion130 & KEYNOTE-355

KEYNOTE-355: HRQoL unaffected by the addition of pembrolizumab to chemotherapy for TNBC

Dr. Rugo on Takeaways From the IMpassion130 Trial in TNBC

“Key Breakthroughs in the Field of Breast Cancer Treatment” by Dr. Hope Rugo

KEYNOTE-355: pembro + chemo in triple-negative breast cancer

Researcher comment: The KEYNOTE-355 trial | Javier Cortes

Medicine Matters oncology

KEYNOTE-355: pembrolizumab in triple-negative breast cancer

Latest on Immunotherapy in Triple-Negative Breast Cancer - Medpage Today

Hope Rugo, MD, discusses the beneficial topics at the 39th Annual Miami Breast Cancer Conference®

Chemoimmunotherapy in TNBC: The KEYNOTE-355 Trial

Hope Rugo, MD, considers the incidence of TNBC and what makes this disease so difficult to treat

Immunotherapy in Breast Cancer

Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer

TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer | Hope Rugo

Medicine Matters oncology

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer

Targeted Oncology